Benitec Biopharma Inc. (BNTC)
Develops genetic medicines that silence disease genes and replace them with healthy ones.
$11.89+0.03%Healthcare
StockGlow Score
Leaning Bearish
BearishBullish
1 year ago+8.5%
The outlook
BNTC is trading well below its 50- and 200-day moving averages, positioned in the lower third of its 52-week range. Analyst sentiment leans bearish overall, though the average price target sits roughly double the current price—a significant gap between current valuation and consensus longer-term view. The stock is essentially flat today.
What’s behind the score
Price trendBelow its 50- & 200-day averages
52-week range30% of the way from its 52-week low to high
Price targetAvg target +103% vs current price
Analyst price target
~12-month · 6 analysts$24.17average target+103.3% vs now
Now $11.89
Low $16.00High $32.00
Published targets from Wall Street analysts (public data) — what analysts expect over roughly a year. This is not a StockGlow forecast and not a recommendation. Analyst targets are frequently wrong.
Market cap
$408.5M
52-wk high
$16.76
52-wk low
$9.85
50-day avg
$11.92
200-day avg
$12.42
Trailing P/E
—